查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1976586

动物血浆製品及衍生市场：按类型、按衍生类型、按最终用户、按应用划分，全球预测（2026-2032年）

Animal Blood Plasma Products & Derivatives Market by Animal Type, Derivative Type, End-User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物血浆製品及衍生市场价值将达到 16.3 亿美元，到 2026 年将成长至 17.5 亿美元，到 2032 年将达到 27.9 亿美元，复合年增长率为 7.99%。

主要市场统计数据
基准年 2025 16.3亿美元
预计年份：2026年 17.5亿美元
预测年份 2032 27.9亿美元
复合年增长率 (%) 7.99%

对动物血浆製品及其衍生进行全面概述，为跨学科相关人员阐明科学、监管和供应链的优先事项。

动物血浆製品及其衍生领域与生命科学、食品加工、兽医学和工业生物技术交叉融合，需要整合技术、监管和商业性观点。本执行摘要係统地评估了该领域的当前趋势，检验了影响竞争力和营运重点的因素，例如产品衍生、最终用途和供应链特征。透过围绕血清和纤维蛋白原等生物原料及其下游应用（包括细胞培养和营养）展开讨论，本分析将这些原料置于传统和新兴价值链中。

技术进步、不断变化的生物安全期望以及永续性压力如何共同作用，重塑该领域的采购、产品一致性和供应商整合。

近年来，在技术和政策的推动下，供应商、製造商和终端用户与动物血浆衍生产品的互动方式正发生着变革性的变化。细胞培养技术和组织工程平台的进步提高了对高品质血清和白蛋白的需求，促使供应商投资于可追溯性系统和更完善的品管流程。同时，加工和分离技术的创新提高了免疫球蛋白和纤维蛋白原製剂的一致性，使其在生物医学研究和特定工业应用中得到更广泛的应用。

了解 2025 年关税调整如何重塑依赖专业生物原料的组织的采购、供应多样化和库存策略。

2025年美国关税调整和贸易政策转变将对整个供应链产生重大影响，改变依赖动物血浆衍生产品的公司的成本结构、供应商选择和库存策略。进口商和下游製造商正在采取应对措施，例如重新评估采购区域、加快供应商多元化计划，并在可能的情况下优先考虑近岸外包。这些战术性措施也伴随着营运方面的变革，例如扩展供应商认证流程和扩大品质保证测试范围，以确保符合法规和客户要求。

我们透过深入的細項分析，将动物来源、衍生产品特性、最终用户合规性和各种应用联繫起来，从而製定客製化的采购和研发策略。

从动物种类、衍生产品种类、最终用户和应用观点进行細項分析，可以揭示不同的动态变化，从而为供应链设计和产品开发提供不同的见解。以动物种类（禽类、牛、羊、猪）为例，原料的可取得性、病原体筛检程序以及文化和监管偏好等方面的差异会影响特定应用对原料的选择。例如，牛源产品通常更适用于某些大批量应用，而当功能特性不同时，则会选择猪源或羊源材料。同样，对牛、纤维蛋白原、免疫球蛋白、血清白蛋白和凝血酶等衍生产品检验，可以发现每种衍生都有其独特的加工、稳定性和品质保证要求，这些要求会影响储存、处理和最终用途检验。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和物流现实决定了供应的连续性、合规性和供应商的选择。

区域性研究揭示了地缘政治、物流和监管因素如何影响动物血浆衍生产品的获取，并影响生产者和消费者的策略选择。在美洲，接近性主要生物技术丛集和成熟的畜牧系统为科研级和工业应用提供了稳健的供应链。低温运输物流基础设施和法律规范促进了区域内的跨境贸易。欧洲、中东和非洲地区呈现出复杂的格局，某些司法管辖区拥有严格的管理体制，而其他地区则具备新兴的生产能力。这要求企业调整其合规策略，并投资与区域供应商建立伙伴关係，以确保产品品质和供应的连续性。

明确竞争优势、品质投资和伙伴关係模式，并制定供应商策略，以创造获得高纯度、大批量衍生性商品的机会。

主要企业之间的竞争趋势揭示了其差异化的策略策略。一些公司专注于生产用于生物医学应用的高纯度衍生物，而其他公司则优先考虑食品和饲料行业的规模和成本效益。市场定位受到品质保证系统、生物安全认证和供应链追踪解决方案投资的影响，这些投资旨在满足受监管终端用户的需求。投资于专有加工技术和严格检验通讯协定的企业，对需要可重复性和完整文件记录的製药和组织工程客户而言，正变得越来越有吸引力。

为领导者提供可操作且优先的行动方案，以加强价值链，整合研发和采购，并透过有针对性的供应商和产品策略创造价值。

产业领导者需要采取一系列切实可行的措施来增强韧性，使研发重点与供给能力保持一致，并在各个应用领域创造价值。首先，投资于整合来源检验、生物安全审计和分析验证的供应商合格框架，将降低下游风险，并缩短受监管应用领域的品质保证时间。其次，在地域和动物种类上实现供应商网路多元化，将降低单一故障点的风险，同时确保获得具有特定功能特性的衍生。第三，透过供应商协作测试和技术转移通讯协定，协调采购和研发部门，将加速产品开发，并确保实验室规模的性能能转化为生产规模的可靠性。

透过结合相关人员访谈、技术整合和供应链映射的严谨、多方面的研究途径，可以产生检验的营运建议。

支持这些研究结果的调查方法结合了与关键相关人员的对话、技术文献整合以及供应链分析，以确保拥有可靠的证据基础，从而为可操作的建议提供支持。关键对话包括与食品、製药和动物医药行业各组织的采购经理、研发经理和品质保证专业人员进行结构化访谈，从而直接观点采购限制、品质期望和物流实际情况。作为这些对话的补充，研究人员还查阅了技术文献和行业指南，以明确每种衍生物的加工要求以及与各种最终用途相关的生物安全注意事项。

策略整合强调检验、供应商多元化和跨部门合作，以确保复杂生物供应链的韧性和技术性能。

总之，动物血浆製品及其衍生涉及的领域兼具科学的复杂性和操作的敏感性，因此需要采取综合策略来管理品质、合规性和连续性。加工技术和应用科学的进步提高了人们对产品可追溯性和批间一致性的期望，而监管和贸易趋势则加剧了对多元化和灵活采购的需求。积极主动地将严格的供应商筛选、策略性的地域多元化以及研发和采购部门之间的协作相结合的相关人员，将能够更有效地降低风险，并抓住生物医学、食品和兽医领域的机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 动物血浆製品及衍生市场：依动物类型划分

  • 鸟类
  • 牛
  • 羊
  • 猪

第九章 动物血浆製品及衍生市场：依衍生类型划分

  • 牛
  • 纤维蛋白原
  • 免疫球蛋白
  • 血清白蛋白
  • 长号

第十章：动物血浆製品及衍生市场：依最终用户划分

  • 动物饲料生产商
  • 製药公司
  • 兽医

第十一章 动物血浆製品及衍生市场：依应用领域划分

  • 动物饲料
  • 生物医学研究
  • 细胞培养基
  • 食品加工
  • 营养补充品
  • 宠物食品业
  • 药品和化妆品
  • 组织工程

第十二章 动物血浆製品及衍生市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 动物血浆製品及衍生市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 动物血浆製品及衍生市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国：动物血浆製品及衍生市场

第十六章 中国：动物血浆製品及衍生市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ACROBiosystems Inc.
  • Alfa Laval Corporate AB
  • ANZCO Foods Limited
  • Auckland BioSciences Ltd.
  • BioChemed Services
  • Biowest Company
  • Bovogen Biologicals Pty Ltd.
  • Canvax Reagents SL
  • Ebrator Biochemicals Inc.
  • Kraeber & Co. GmbH
  • Lake Immunogenics, Inc.
  • LAMPIRE Biological Laboratories, Inc.
  • Meiji Holdings Co., Ltd.
  • Merck KGaA
  • Pel-Freez, LLC
  • Rockland Immunochemicals, Inc.
  • Rocky Mountain Biologicals
  • Scripps Laboratories, Inc.
  • Sigma-Aldrich
  • TCS Biosciences Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0E2

The Animal Blood Plasma Products & Derivatives Market was valued at USD 1.63 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, with a CAGR of 7.99%, reaching USD 2.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.63 billion
Estimated Year [2026] USD 1.75 billion
Forecast Year [2032] USD 2.79 billion
CAGR (%) 7.99%

A comprehensive orientation to animal blood plasma products and derivatives that clarifies scientific, regulatory, and supply chain priorities for interdisciplinary stakeholders

The animal blood plasma products and derivatives landscape intersects life sciences, food processing, veterinary care, and industrial biotechnology, demanding a synthesis of technical, regulatory, and commercial perspectives. This executive summary introduces a structured appraisal of the sector's current dynamics, examining product derivatives, end-use applications, and supply chain characteristics that together shape competitive and operational priorities. By framing the conversation around biological inputs such as serum and fibrinogen as well as downstream applications spanning cell culture and nutrition, the analysis situates these materials within both traditional and emerging value chains.

This introduction highlights the necessity for stakeholders to balance scientific rigor with supply chain agility. Shifts in sourcing strategies, evolving quality expectations for biomedical and food-grade derivatives, and the cross-sectoral nature of demand underscore the importance of integrated decision-making. Consequently, the report emphasizes practical insights that align laboratory needs, regulatory compliance, and commercial imperatives, enabling organizations to prioritize investments in quality assurance, supplier relationships, and application-specific product development.

How technological advances, evolving biosafety expectations, and sustainability pressures are jointly reshaping sourcing, product consistency, and supplier integration in the sector

Recent developments have triggered transformative shifts in how suppliers, manufacturers, and end-users approach animal blood plasma derivatives, with technology and policy acting as primary accelerants. Advances in cell-culture techniques and tissue-engineering platforms have increased demand for high-quality serum and albumin, prompting suppliers to invest in traceability systems and enhanced quality control processes. Concurrently, innovations in processing and fractionation have improved the consistency of immunoglobulin and fibrinogen preparations, enabling wider adoption in both biomedical research and specialized industrial uses.

Regulatory evolution is reshaping procurement and validation approaches. Stricter documentation and biosafety expectations have elevated the importance of supplier vetting and provenance assurance, especially for applications with human-health implications. In parallel, sustainability considerations are prompting upstream changes in sourcing and waste management, incentivizing closed-loop practices and alternative sourcing strategies. These converging forces are driving a reconfiguration of supplier portfolios and encouraging vertical integration by firms seeking to secure raw materials and control quality. As a result, organizations that align R&D priorities with supplier capability and regulatory foresight are positioning themselves to capitalize on emerging technical opportunities while mitigating operational disruption.

Understanding how 2025 tariff adjustments reshaped procurement, supplier diversification, and inventory strategies for organizations dependent on specialized biological inputs

Tariff adjustments and trade policy shifts in the United States for 2025 have had material implications across the supply chain, altering cost structures, supplier selection, and inventory strategies for businesses reliant on animal blood plasma derivatives. Importers and downstream manufacturers have responded by reassessing sourcing geographies, accelerating supplier diversification plans, and increasing emphasis on nearshoring where feasible. These tactical responses have been accompanied by operational changes such as extended supplier qualification timelines and expanded quality assurance testing to ensure conformity with both regulatory and customer specifications.

The tariff environment has also influenced commercial negotiations and contractual terms, with buyers seeking more flexible pricing arrangements and suppliers negotiating longer-term contracts to stabilize revenue streams. Logistic patterns have adjusted in response, with companies reallocating inventory buffers across regional distribution centers to mitigate potential customs delays and cost volatility. For technology-driven users of serum and specialized proteins, procurement teams are balancing the need for high-certainty supply with cost management, often prioritizing validated suppliers with regional production capabilities. Overall, the tariff context has increased the premium on supply chain transparency, redundancy, and contractual agility to sustain research timelines and production continuity.

Deep segmentation insights that connect animal source, derivative characteristics, end-user compliance, and diverse applications to inform tailored sourcing and R&D strategies

Segmentation analysis reveals differentiated dynamics when observed through the lenses of animal type, derivative type, end-user, and application, each offering distinct implications for supply chain design and product development. When considering animal type-Avian, Bovine, Ovine, and Porcine-differences in source availability, pathogen screening protocols, and cultural or regulatory preferences influence which raw materials are favored for specific applications, with bovine-derived products commonly prioritized for certain high-volume applications and porcine or ovine materials selected where functional properties differ. In parallel, examining derivative types such as Fetal Bovine Serum, Fibrinogen, Immunoglobulin, Serum Albumin, and Thrombin clarifies that each derivative carries unique processing, stability, and quality assurance requirements that affect storage, handling, and end-use validation.

End-user segmentation across Food Manufacturers, Pharmaceutical Companies, and Veterinary sectors highlights divergent compliance frameworks and performance expectations: food processors emphasize food-safety certifications and allergen control, pharmaceutical firms prioritize traceability and regulatory documentation, and veterinary users balance efficacy with cost and shelf-life considerations. Application-driven distinctions-spanning Animal Feed, Biomedical Research, Cell Culture Media, Food Processing, Nutrition Supplements, Pet Food Industry, Pharmaceuticals & Cosmetics, and Tissue Engineering-illustrate variation in purity, functional specification, and value capture. For instance, biomedical research and cell culture demand stringent lot-to-lot consistency and contamination controls, while applications in animal feed and pet food tolerate broader specification ranges but require cost-efficient supply. Integrating these segmentation perspectives enables stakeholders to tailor sourcing, quality management, and product development roadmaps that reflect both technical constraints and commercial priorities.

Regional dynamics and logistical realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine supply continuity, compliance, and supplier choice

Regional insights illuminate how geopolitical, logistical, and regulatory factors shape access to animal blood plasma derivatives and influence strategic choices by producers and consumers. In the Americas, proximity to major biotech clusters and established animal agriculture systems supports robust supply chains for both research-grade and industrial applications, with infrastructure geared toward cold-chain logistics and regulatory oversight that facilitates cross-border trade within the region. Europe, Middle East & Africa presents a complex mosaic where stringent regulatory regimes in certain jurisdictions coexist with emerging production capacity in others, prompting companies to adapt compliance strategies and invest in regional supplier partnerships to assure quality and continuity.

Asia-Pacific has become increasingly pivotal, combining large-scale animal production capacity with expanding biomanufacturing and research activity. This region's logistical scale and cost efficiencies can offer advantages to global firms, though buyers must navigate heterogeneous regulatory landscapes and varying quality assurance norms. Across all regions, regional regulatory expectations, transport infrastructure, and source animal availability drive procurement decisions and strategic supplier alignment. Consequently, organizations that map regional strengths against application-specific requirements are better positioned to optimize supply continuity, reduce lead times, and manage compliance risk.

Competitive positioning and supplier strategies that delineate specialization, quality investment, and partnership models shaping access to high-purity and large-volume derivatives

Competitive dynamics among key companies reveal differentiated strategic approaches, with some firms focusing on specialization in high-purity derivatives for biomedical applications while others emphasize scale and cost-efficiency for food and feed segments. Market positions are influenced by investments in quality assurance systems, biosafety certifications, and supply chain traceability solutions that respond to the demands of regulated end-users. Organizations investing in proprietary processing technologies and rigorous validation protocols are increasingly attractive to pharmaceutical and tissue-engineering customers that require reproducibility and documentation.

Strategic partnerships and contract manufacturing relationships also shape competitive advantage. Firms that integrate forward into value-added services-such as custom formulation support, regulatory dossier assistance, and application-specific testing-tend to capture higher-margin relationships with research institutions and specialty manufacturers. Meanwhile, producers focused on commodity-grade derivatives leverage scale and cost management to maintain relevance in large-volume applications like animal feed and pet food. Observing these varied strategies enables stakeholders to benchmark potential suppliers against operational needs and to prioritize partners whose capabilities align with product specifications, compliance requirements, and long-term reliability.

Practical and prioritized actions for leaders to fortify supply chains, synchronize R&D with procurement, and capture value through targeted supplier and product strategies

Industry leaders must adopt a set of pragmatic, actionable steps to strengthen resilience, align R&D priorities with supply capabilities, and capture value across applications. First, investing in supplier qualification frameworks that integrate provenance verification, biosafety audits, and analytical validation will reduce downstream risk and shorten time-to-assurance for regulated applications. Second, diversifying supplier networks geographically and across animal sources can mitigate exposure to single-point disruptions while enabling access to derivatives with specific functional properties. Third, aligning procurement and R&D teams through joint supplier trials and technical transfer protocols will accelerate product development and ensure that laboratory-scale performance translates into production-scale reliability.

Additionally, companies should develop adaptive contracting approaches that balance price stability with flexibility for quality and volume adjustments, and they should incorporate inventory strategies that reflect application criticality rather than uniform stocking rules. For product developers, prioritizing formulations that accommodate broader input variability where possible will reduce sensitivity to supplier fluctuation. Finally, engaging proactively with regulators and standard-setting bodies to influence or anticipate compliance requirements will yield advantages in time-to-market and reduce rework. By operationalizing these recommendations, organizations can transform insight into resilient procurement, robust product pipelines, and sustained competitive differentiation.

A rigorous, multi-method research approach combining stakeholder interviews, technical synthesis, and supply chain mapping to generate validated operational recommendations

The research methodology underpinning these insights combines primary stakeholder engagement, technical literature synthesis, and supply chain analysis to ensure a robust evidence base that supports actionable recommendations. Primary engagement included structured interviews with procurement leads, R&D heads, and quality assurance professionals across food, pharmaceutical, and veterinary organizations, providing firsthand perspectives on sourcing constraints, quality expectations, and logistical realities. Complementing these dialogues, a review of technical literature and industry guidelines clarified derivative-specific processing requirements and biosafety considerations relevant to different end uses.

Supply chain mapping and trade-flow analysis were conducted to identify common bottlenecks and resilience levers, with attention to cold-chain demands, cross-border compliance, and supplier concentration. Triangulation of qualitative inputs with operational indicators allowed for the development of pragmatic recommendations focused on supplier qualification, contractual design, and inventory management. Throughout, methodological rigor was maintained by documenting assumptions, validating findings through multiple stakeholder perspectives, and prioritizing transparency in analytic steps to support reproducibility and confidence in the implications drawn for practitioners.

A strategic synthesis that emphasizes validation, supplier diversification, and cross-functional alignment to ensure resilience and technical performance in complex biological supply chains

In summary, animal blood plasma products and derivatives occupy a nexus of scientific complexity and operational sensitivity that requires integrated strategies to manage quality, compliance, and continuity. Advances in processing and application science have elevated expectations for traceability and lot consistency, while regulatory and trade dynamics have amplified the need for diversified sourcing and agile procurement. Stakeholders who proactively combine rigorous supplier qualification, strategic geographic diversification, and alignment between research and procurement functions will better mitigate risk and seize opportunities across biomedical, food, and veterinary arenas.

Ultimately, the sector rewards organizations that treat biological inputs not merely as commodities but as critical components of broader product and research ecosystems. By investing in validation, fostering strategic supplier relationships, and embedding regulatory foresight into procurement decisions, institutions can ensure operational resilience and maintain the technical performance that underpins end-user trust and innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Blood Plasma Products & Derivatives Market, by Animal Type

  • 8.1. Avian
  • 8.2. Bovine
  • 8.3. Ovine
  • 8.4. Porcine

9. Animal Blood Plasma Products & Derivatives Market, by Derivative Type

  • 9.1. Fetal Bovine Serum
  • 9.2. Fibrinogen
  • 9.3. Immunoglobulin
  • 9.4. Serum Albumin
  • 9.5. Thrombin

10. Animal Blood Plasma Products & Derivatives Market, by End-User

  • 10.1. Food Manufacturers
  • 10.2. Pharmaceutical Companies
  • 10.3. Veterinary

11. Animal Blood Plasma Products & Derivatives Market, by Application

  • 11.1. Animal Feed
  • 11.2. Biomedical Research
  • 11.3. Cell Culture Media
  • 11.4. Food Processing
  • 11.5. Nutrition Supplements
  • 11.6. Pet Food Industry
  • 11.7. Pharmaceuticals & Cosmetics
  • 11.8. Tissue Engineering

12. Animal Blood Plasma Products & Derivatives Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Blood Plasma Products & Derivatives Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Blood Plasma Products & Derivatives Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Animal Blood Plasma Products & Derivatives Market

16. China Animal Blood Plasma Products & Derivatives Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ACROBiosystems Inc.
  • 17.6. Alfa Laval Corporate AB
  • 17.7. ANZCO Foods Limited
  • 17.8. Auckland BioSciences Ltd.
  • 17.9. BioChemed Services
  • 17.10. Biowest Company
  • 17.11. Bovogen Biologicals Pty Ltd.
  • 17.12. Canvax Reagents S.L.
  • 17.13. Ebrator Biochemicals Inc.
  • 17.14. Kraeber & Co. GmbH
  • 17.15. Lake Immunogenics, Inc.
  • 17.16. LAMPIRE Biological Laboratories, Inc.
  • 17.17. Meiji Holdings Co., Ltd.
  • 17.18. Merck KGaA
  • 17.19. Pel-Freez, LLC
  • 17.20. Rockland Immunochemicals, Inc.
  • 17.21. Rocky Mountain Biologicals
  • 17.22. Scripps Laboratories, Inc.
  • 17.23. Sigma-Aldrich
  • 17.24. TCS Biosciences Ltd.
  • 17.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY OVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FETAL BOVINE SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FIBRINOGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SERUM ALBUMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY THROMBIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY BIOMEDICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY CELL CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY FOOD PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY NUTRITION SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PET FOOD INDUSTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY PHARMACEUTICALS & COSMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY DERIVATIVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ANIMAL BLOOD PLASMA PRODUCTS & DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)